Aurobindo Pharma Gets USFDA’s Provisional Approval

Aurobindo Pharma Gets USFDA’s Provisional ApprovalAs per recent reports, it has been revealed that drug firm Aurobindo Pharma has received provisional approvals from the US regulators for its anti-AIDS combination drug named as Efavirenz/Emtricitabine and Tenofovir Disoproxil Fumarate tablets.

The US Food and Drug Administration (USFDA) has given provisional approvals for the drug which is available in different strengths like 600mg, 200mg and 300mg.

"The company is one of the first generics firm to have received the tentative approval to manufacture and market its anti-AIDS combination drug Efavirenz / Emtricitabine and Tenofovir Disoproxil Fumarate Tablets", said Aurobindo Pharma.

It is said that the combination drug is equivalent to Atripla tablets of Gilead Sciences Inc.  The news has helped to bring a rise in shares of the company and that too by 2.45% amounting to Rs 161.30 apiece.

Authorities concerned were of the view that Aurobindo Pharma now has as many as 182 abbreviated new drug application (ANDA) approvals. Out of 182, the company has 156 confirmed approvals and other 26 are tentative.

In addition, it has been revealed that the company's stock has been performing quite well in last four trading sessions. It has been said so as the company has seen a rise of 24% in past four trading sessions.